OCA
AZN icon

Odyssey Capital Advisors’s AstraZeneca AZN Stock Holding History

Odyssey Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$319K Hold
1,683
– – 0.23% 87
2026
Q1 		$332K Buy
1,683
+66
+4% +$12.7K 0.3% 75
2025
Q4 		$297K Buy
+1,617
New +$284K 0.26% 81

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Odyssey Capital Advisors's AZN Position: Q2 2026 in Review

Odyssey Capital Advisors held its AstraZeneca (AZN) position steady in Q2 2026 at 1,683 shares worth $319K. The position accounts for 0.23% of the portfolio, ranked #87.

Odyssey Capital Advisors first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $332K in Q1 2026. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Odyssey Capital Advisors held 1,683 shares of AstraZeneca worth $319K as of Q2 2026.
  • Odyssey Capital Advisors left its AstraZeneca share count unchanged in Q2 2026.
  • AstraZeneca made up 0.23% of Odyssey Capital Advisors's portfolio in Q2 2026, its #87 holding.
  • Odyssey Capital Advisors first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
  • Odyssey Capital Advisors's AstraZeneca position peaked at $332K in Q1 2026.
  • 1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Odyssey Capital Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.